NCT07216651View on ClinicalTrials.gov

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Obesity & Overweight
Trial Locations (1)

37067

RECRUITING

Amarillo Premier Research (an Objective Health Partnership), Amarillo

Sponsors
All Listed Sponsors
lead

Closed Loop Medicine

INDUSTRY

NCT07216651 - WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults | Biotech Hunter | Biotech Hunter